Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Cancer
Lymphoma

Interventions: Drug: XL147 (SAR245408)

First Posted Date: 2007-06-13

Last Posted Date: 2013-02-01

Lead Sponsor: Sanofi

Target Recruit Count: 118

Registration Number: NCT00486135

Locations: 🇺🇸
Investigational Site Number 1503, Boston, Massachusetts, United States
🇺🇸
Investigational Site Number 1241, Augusta, Georgia, United States
🇪🇸
Investigational Site Number 3412, Barcelona, Spain

and more 1 locations

Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: larotaxel (XRP9881)
Drug: docetaxel
Drug: trastuzumab

First Posted Date: 2007-06-13

Last Posted Date: 2011-06-28

Lead Sponsor: Sanofi

Target Recruit Count: 330

Registration Number: NCT00485979

Locations: 🇺🇾
Sanofi-Aventis Administrative Office, Montevideo, Uruguay

Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients

Phase 3

Completed

Conditions: Obesity

First Posted Date: 2007-06-04

Last Posted Date: 2009-04-20

Lead Sponsor: Sanofi

Target Recruit Count: 156

Registration Number: NCT00481923

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guilford, United Kingdom

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

Phase 3

Completed

Conditions: Obesity
Eating Disorders

First Posted Date: 2007-06-04

Last Posted Date: 2009-04-07

Lead Sponsor: Sanofi

Target Recruit Count: 289

Registration Number: NCT00481975

Locations: 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

Phase 3

Terminated

Conditions: Obesity
Diabetes Mellitus Type 2

Interventions: Drug: Rimonabant
Drug: Placebo (for Rimonabant)
Drug: Anti-diabetic monotherapy

First Posted Date: 2007-05-25

Last Posted Date: 2016-06-06

Lead Sponsor: Sanofi

Target Recruit Count: 458

Registration Number: NCT00478595

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2007-05-25

Last Posted Date: 2011-01-26

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT00479076

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise

Phase 3

Terminated

Conditions: Obesity
Diabetes Mellitus Type 2

Interventions: Drug: Rimonabant
Drug: placebo (for Rimonabant)
Other: Diet and exercise

First Posted Date: 2007-05-25

Last Posted Date: 2016-06-08

Lead Sponsor: Sanofi

Target Recruit Count: 321

Registration Number: NCT00478972

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: depakine chrono

First Posted Date: 2007-05-23

Last Posted Date: 2008-12-19

Lead Sponsor: Sanofi

Target Recruit Count: 70

Registration Number: NCT00477373

Locations: 🇶🇦
Sanofi-aventis administrative office, Qatar, Qatar
🇴🇲
Sanofi-Aventis Administrative Office, Muscat, Oman

Practicability and Acceptability of Stylomax® in Children

Phase 3

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: somatropine

First Posted Date: 2007-05-22

Last Posted Date: 2009-02-12

Lead Sponsor: Sanofi

Target Recruit Count: 12

Registration Number: NCT00476385

Locations: 🇫🇷
Sanofi-Aventis, Paris, France

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo (for teriflunomide)
Drug: Teriflunomide
Drug: Glatiramer Acetate (GA)

First Posted Date: 2007-05-21

Last Posted Date: 2012-11-06

Lead Sponsor: Sanofi

Target Recruit Count: 123

Registration Number: NCT00475865

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom

Home Terms & Conditions Privacy Policy